LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Lista de Ações・Compugen Ltd

Compugen Ltd

Fechado

2.03 -2.87

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

2.12

Indicadores-chave
By Trading Economics
Rendimento	-65M -7.7M
Vendas	-65M 2.2M
P/E Médio do Setor	6.474 49.888
EPS	-0.08
Margem de lucro	-352.436
Funcionários	75
EBITDA	-64M -7.7M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+138.1% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-38M 233M
Abertura anterior	4.9
Fecho anterior	2.03

Compugen Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de jun. de 2026, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 de jun. de 2026, 15:41 UTC

Grandes Movimentos do Mercado

American Battery Shares Jump on Energy Department Victory

8 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 de jun. de 2026, 23:37 UTC

Conversa de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 de jun. de 2026, 23:25 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 de jun. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Salesforce Agrees to Buy m3ter

8 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

8 de jun. de 2026, 19:22 UTC

Conversa de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 de jun. de 2026, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

8 de jun. de 2026, 18:52 UTC

Conversa de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 de jun. de 2026, 18:17 UTC

Conversa de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 de jun. de 2026, 17:32 UTC

Conversa de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 de jun. de 2026, 17:29 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de jun. de 2026, 16:55 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 de jun. de 2026, 16:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 de jun. de 2026, 16:40 UTC

Conversa de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 16:31 UTC

Conversa de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 de jun. de 2026, 16:27 UTC

Conversa de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 de jun. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de jun. de 2026, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Bought Stake From Lorca

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 de jun. de 2026, 16:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Orange Acquires 100% Ownership of MasOrange

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

8 de jun. de 2026, 15:58 UTC

Conversa de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 de jun. de 2026, 15:55 UTC

Conversa de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 de jun. de 2026, 15:41 UTC

Conversa de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparação entre Pares

Variação de preço

Compugen Ltd Previsão

Preço-alvo

By TipRanks

138.1% parte superior

Previsão para 12 meses

Média 5 USD 138.1%

Máximo 6 USD

Mínimo 4 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Compugen Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

Comprar

Manter

Vender

Com base em 3 analistas que deram avaliações de ações para Compugen Ltd - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.